Loading financials from SEC filings…
Specialty industrial machinery · Industrials · Fiscal year ends May 31
ChronoScale reported revenue of $72M in the fiscal year ended May 2026, up 459.4% from the year before. Operating income was −$37M, an operating margin of −52.4%, and net income was −$50M. Operating cash flow of $39M less capital expenditure of $27M left free cash flow of $12M. It held more cash than debt (net cash $6M).
Ranks among the 34 specialty industrial machinery companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2023 | Dec 2024 | May 2025 | Dec 2025 | May 2026 |
|---|---|---|---|---|---|
| Revenue | 18.3 | 17.9 | 84.4 | 12.8 | 71.6 |
| Cost of revenue | 9.2 | 8.4 | 115 | 6.0 | 88.7 |
| Gross profit | 9.1 | 9.5 | −30.9 | 6.8 | −17.1 |
| Research & development | 5.0 | 3.9 | – | 3.0 | – |
| Selling, general & admin | 19.2 | 16.1 | 24.8 | 17.1 | 19.8 |
| Operating income | −15.1 | −10.5 | −55.3 | −13.3 | −37.5 |
| Interest expense | 0.3 | 0.3 | – | 0.3 | – |
| Pre-tax income | −15.2 | −11.3 | −72.7 | −11.7 | −49.3 |
| Income tax | – | – | 0.0 | 0.0 | 0.0 |
| Net income | −15.2 | −11.3 | −72.7 | −11.7 | −50.3 |
| Diluted EPS | −1.10 | −8.43 | −0.53 | −4.91 | −0.36 |
| Diluted shares | 13.9 | 20.2 | 138 | – | 139 |
| Fiscal year | Dec 2023 | Dec 2024 | May 2025 | Dec 2025 | May 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | 8.6 | 4.5 | 2.4 | 1.2 | 9.7 |
| Receivables | 5.6 | 7.2 | 3.8 | 7.3 | 12.5 |
| Inventory | 5.1 | 4.6 | – | 4.8 | – |
| Current assets | 20.2 | 18.8 | 6.4 | 14.0 | 44.2 |
| Net PP&E | 2.0 | 1.6 | 10.9 | 1.3 | 32.1 |
| Goodwill | 0.4 | 0.4 | 0.0 | 0.4 | 54.5 |
| Total assets | 28.9 | 26.7 | 304 | 20.1 | 326 |
| Payables | 1.8 | 1.6 | 4.0 | 1.4 | 9.1 |
| Deferred revenue | 2.0 | 2.0 | 3.6 | 1.7 | 0.0 |
| Current liabilities | 8.1 | 7.5 | 158 | 8.6 | 86.9 |
| Short-term debt | – | – | 0.0 | – | 3.4 |
| Long-term debt | 4.8 | 3.9 | 12.0 | 0.8 | 0.5 |
| Total liabilities | 16.3 | 13.9 | 228 | 11.1 | 144 |
| Shareholders' equity | 12.6 | 12.7 | 76.2 | 9.0 | 180 |
| Fiscal year | Dec 2023 | Dec 2024 | May 2025 | Dec 2025 | May 2026 |
|---|---|---|---|---|---|
| Operating cash flow | −12.1 | −9.8 | −7.2 | −11.8 | 39.1 |
| Capital expenditure | 0.2 | 0.0 | 1.4 | 0.2 | 26.9 |
| Free cash flow | −12.2 | −9.9 | −8.6 | −12.0 | 12.2 |
| Depreciation & amortisation | 1.7 | 1.6 | 80.7 | 1.6 | 60.3 |
| Stock-based compensation | 1.9 | 1.4 | −1.5 | 1.5 | 1.3 |
| Fiscal year | Dec 2023 | Dec 2024 | May 2025 | Dec 2025 | May 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | −1.9% | 370.7% | −84.8% | 459.4% |
| Gross margin | 49.7% | 53.1% | −36.7% | 53.5% | −23.9% |
| Operating margin | −82.7% | −58.4% | −65.6% | −104.1% | −52.4% |
| Net margin | −83.1% | −63.2% | −86.2% | −91.4% | −70.3% |
| Return on equityBlank when equity is negative | −120.6% | −89.2% | −95.5% | −129.6% | −28.0% |
| ROCEEBIT ÷ (assets − current liabilities) | −72.7% | −54.7% | −37.8% | −116.1% | −15.7% |
| Free cash flow margin | −66.8% | −55.1% | −10.2% | −93.7% | 17.0% |
| Cash conversion (CFO ÷ net income) | 0.79x | 0.87x | 0.10x | 1.01x | −0.78x |
| Receivable days | 113 | 147 | 16 | 208 | 64 |
| Inventory days | 200 | 198 | – | 296 | – |
| Payable days | 73 | 67 | 13 | 88 | 37 |
| Interest cover | −50.0x | −38.9x | – | −43.1x | – |
| Debt ÷ equity | 0.38x | 0.30x | 0.16x | 0.09x | 0.02x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | −3.8 | −0.6 | 9.6 | −0.4 | −5.8 |
| Current ratio | 2.49x | 2.50x | 0.04x | 1.63x | 0.51x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.